AlphAIAlphAI — Financial news for AI agents
investorsking.comOCT 122 min read

Multi-Trex Shares Jump 16.7% After NGX Ends Nearly Eight-Year Suspension

Multi-Trex Integrated Foods Plc's shares rose 16.67% after the Nigerian Exchange Limited (NGX) lifted an eight-year trading suspension. The stock increased from N0.36 to N0.42 per share, ranking among the top five gainers on the NGX. The suspension was lifted after Multi-Trex filed required financial statements, resuming trading activity. The stock was highly traded, with over 27 million shares exchanged. This occurred amid a broader market decline, with the NGX All-Share Index falling 0.97%.

Original reporting
investorsking.com
Published Oct 12, 2026, 8:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Multi-Trex Shares Jump 16.7% After NGX Ends Nearly Eight-Year Suspension — source image
Source · investorsking.com
Decision brief

The 30-second read

Low
01

Why it matters

The suspension lift triggered a 16.7% price increase, making the stock one of the week’s top gainers on the NGX.

02

Market read

First report of a rare suspension lift leading to a notable intraday rally on a small‑cap Nigerian stock.

03

What to watch

Liquidity constraints and potential future compliance issues could cap upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Multi-Trex Integrated Foods Plc had been suspended from trading on the NGX since 2018 for filing failures. The exchange lifted the suspension after the company filed the required statements.

Market effects

Sector

Limited to Nigerian consumer foods sector; modest impact.

Regional

Minor boost to Nigerian Exchange activity after a rare suspension lift.

Global

None

Counterpoint

What could challenge this read

The price jump may be a short‑term rebound with limited fundamentals.

Key entities

  • company
    Multi-Trex Integrated Foods Plc

    Nigerian food producer whose shares resumed trading after an eight‑year suspension.

  • exchange
    Nigerian Exchange Limited (NGX)

    Regulatory body that lifted the trading suspension.

Read at source← All news

Related articles

OCT 9
HighAI 8/10

TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO

TRex Bio filed for a Nasdaq IPO, offering 8,333,334 shares at $14.00 each, aiming to raise $116.7 million. The company, focused on immunoregulatory medicines, plans to use proceeds for clinical trials and general corporate purposes. Eli Lilly has shown interest in purchasing shares. TRex Bio's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027.

tradingview.com2 min
OCT 9
HighAI 8/10

TRex Bio raises $116.7 million in IPO priced at $14 a share

TRex Bio Inc. raised $116.7 million in its IPO, priced at $14 per share. J.P. Morgan and Evercore led the offering, indicating institutional confidence. The company focuses on immunology, an area of sustained investor interest. All shares were pre-allocated to institutional buyers, with the first public trading opportunity upcoming.

247wallst.com2 min
OCT 9
HighAI 8/10

TRex Bio IPO raises $116.7 million, prices at bottom of range

TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.

finance.yahoo.com2 min
OCT 9
HighAI 8/10

TRex Bio prices $117M IPO to support immune drug work

TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.

finance.yahoo.com2 min
OCT 9
HighAI 9/10

TRex Bio, Inc. Prices $116.7M IPO at $14

TRex Bio priced 8.3M shares at $14 each, raising $116.7M in its IPO. Trading begins Oct. 9 on Nasdaq under ticker TRXB. Underwriters have a 30-day option for 1.25M more shares. The company plans to use proceeds for its clinical-stage immunology pipeline.

tradingview.com1 min